ATE364048T1 - Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität - Google Patents

Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität

Info

Publication number
ATE364048T1
ATE364048T1 AT04011673T AT04011673T ATE364048T1 AT E364048 T1 ATE364048 T1 AT E364048T1 AT 04011673 T AT04011673 T AT 04011673T AT 04011673 T AT04011673 T AT 04011673T AT E364048 T1 ATE364048 T1 AT E364048T1
Authority
AT
Austria
Prior art keywords
cea
peptides
carcinoembryonic antigen
antagonistic activity
tachykinin antagonistic
Prior art date
Application number
AT04011673T
Other languages
English (en)
Inventor
Jeffrey Schlom
Nee Barzaga Maria Elen Salazar
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE364048T1 publication Critical patent/ATE364048T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464482—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AT04011673T 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität ATE364048T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
ATE364048T1 true ATE364048T1 (de) 2007-06-15

Family

ID=22036775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04011673T ATE364048T1 (de) 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Country Status (11)

Country Link
EP (1) EP1017810B1 (de)
JP (1) JP4291508B2 (de)
AT (2) ATE364048T1 (de)
AU (1) AU745863B2 (de)
CA (1) CA2308127C (de)
CY (1) CY1107706T1 (de)
DE (2) DE69837896T2 (de)
DK (1) DK1447414T3 (de)
ES (2) ES2286530T3 (de)
PT (1) PT1447414E (de)
WO (1) WO1999019478A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
PT1092779E (pt) * 1999-10-11 2010-01-19 Pasteur Institut Vectores lentivíricos para a preparação de composições imunoterapêuticas
ATE395930T1 (de) * 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
CA2416893A1 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Modified cea and uses thereof
WO2003059379A2 (en) * 2002-01-17 2003-07-24 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
EP1567014B1 (de) * 2002-12-04 2011-09-28 Baylor Research Institute Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
CN104147597A (zh) * 2002-12-16 2014-11-19 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7457855B2 (en) 2004-04-30 2008-11-25 Aol Llc Network configuration management
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
BRPI0814140A2 (pt) 2007-07-27 2017-03-28 Immatics Biotechnologies Gmbh composição de peptídeos associados a tumor e vacina anticâncer relacionada
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
EP2419126B1 (de) 2009-04-17 2018-01-10 Globeimmune, Inc. Kombinationsimmuntherapie und zusammensetzungen gegen krebs und verfahren
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
CA2973109A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for ebola virus vaccination
EP3286213B1 (de) 2015-04-20 2021-08-04 Etubics Corporation Verfahren und zusammensetzungen für eine kombinationsimmuntherapie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2206446T3 (es) * 1991-05-06 2004-05-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Virus recombinante que expresa un antigeno carcinoembrionico y metodos de uso del mismo.
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
EP1017810B1 (de) 2004-05-19
DE69824023T2 (de) 2005-05-12
DE69824023D1 (de) 2004-06-24
DE69837896T2 (de) 2008-02-14
PT1447414E (pt) 2007-07-18
JP2002500002A (ja) 2002-01-08
ES2217585T3 (es) 2004-11-01
CA2308127A1 (en) 1999-04-22
JP4291508B2 (ja) 2009-07-08
AU745863B2 (en) 2002-04-11
DE69837896D1 (de) 2007-07-19
AU9500498A (en) 1999-05-03
WO1999019478A1 (en) 1999-04-22
ES2286530T3 (es) 2007-12-01
CY1107706T1 (el) 2013-04-18
DK1447414T3 (da) 2007-09-10
EP1017810A1 (de) 2000-07-12
CA2308127C (en) 2011-03-22
ATE267213T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
ATE364048T1 (de) Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
EA199800946A1 (ru) Концентрированный препарат антител
DE69533923D1 (de) Cytokinin-designiertes lerk-5
ATE188486T1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
ATE259377T1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
TR200000654T2 (tr) KAY-Yeni bir bağışıklık sistemi proteini.
DE3787002T2 (de) Synthetische Peptide, die zelluläre Immunität gegen den AIDS-Virus und dessen Proteine erzeugen.
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
AU4966693A (en) Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
DE3485229D1 (de) Shampoo-praeparate.
ATE387458T1 (de) Fas-antigenbindender ligand
DE69938786D1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
EP0851030A4 (de) PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER
HU9300900D0 (en) Human gamma-interferon antagonists
DE69227898T2 (de) Rekombinante hybride porinepitope
DE69637078D1 (de) Polypeptid-fragmente die fähig sind mit dem antigen i/ii von streptococcus mutans zu konkurrieren
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
EP1447414A3 (de) Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
SE8502540D0 (sv) Stable dentifrice containing dextranase
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
ES2006730A6 (es) Un metodo de preparar un peptido o polipeptido sintetico que presenta la antigenicidad de la totalidad o una parte de un antigeno de p. falciparum
DE59814002D1 (de) Sekretion von tragergebundenen proteinen in das periplasma und in den extrazellulären raum

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1447414

Country of ref document: EP